These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 16264139)

  • 1. Effect of bisphosphonates on periprosthetic bone mineral density after total joint arthroplasty.
    Shetty NR; Hamer AJ; Stockley I; Eastell R; Wilkinson JM
    J Bone Joint Surg Am; 2005 Nov; 87(11):2589-90; author reply 2590. PubMed ID: 16264139
    [No Abstract]   [Full Text] [Related]  

  • 2. Bisphosphonates for the preservation of periprosthetic bone mineral density after total joint arthroplasty: a meta-analysis of 25 randomized controlled trials.
    Shi M; Chen L; Xin Z; Wang Y; Wang W; Yan S
    Osteoporos Int; 2018 Jul; 29(7):1525-1537. PubMed ID: 29654342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic analysis of bisphosphonate intervention on periprosthetic BMD as a function of stem design.
    Knusten AR; Ebramzadeh E; Longjohn DB; Sangiorgio SN
    J Arthroplasty; 2014 Jun; 29(6):1292-7. PubMed ID: 24703781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of bisphosphonates on periprosthetic bone mineral density after total joint arthroplasty. A meta-analysis.
    Bhandari M; Bajammal S; Guyatt GH; Griffith L; Busse JW; Schünemann H; Einhorn TA
    J Bone Joint Surg Am; 2005 Feb; 87(2):293-301. PubMed ID: 15687150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of bisphosphonates on periprosthetic bone loss after total knee arthroplasty: a meta-analysis of randomized controlled trials.
    Shi M; Chen L; Wu H; Wang Y; Wang W; Zhang Y; Yan S
    BMC Musculoskelet Disord; 2018 May; 19(1):177. PubMed ID: 29848366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of zoledronic acid on reducing femoral bone mineral density loss following total hip arthroplasty: A meta-analysis from randomized controlled trails.
    Gao J; Gao C; Li H; Wang GS; Xu C; Ran J
    Int J Surg; 2017 Nov; 47():116-126. PubMed ID: 28827056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates for periprosthetic bone loss after joint arthroplasty: a meta-analysis of 14 randomized controlled trials.
    Lin T; Yan SG; Cai XZ; Ying ZM
    Osteoporos Int; 2012 Jun; 23(6):1823-34. PubMed ID: 21932113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impacts on bone mineral density].
    Kurth A
    Orthopade; 2014 Feb; 43(2):182. PubMed ID: 24693554
    [No Abstract]   [Full Text] [Related]  

  • 9. Bisphosphonates for osteoporosis--where do we go from here?
    Whitaker M; Guo J; Kehoe T; Benson G
    N Engl J Med; 2012 May; 366(22):2048-51. PubMed ID: 22571168
    [No Abstract]   [Full Text] [Related]  

  • 10. Current controversies in bisphosphonate therapy.
    Paul GR
    Orthopedics; 2010 Jul; 33(7):468. PubMed ID: 20608598
    [No Abstract]   [Full Text] [Related]  

  • 11. Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis.
    Voskaridou E; Christoulas D; Antoniadou L; Terpos E
    Acta Haematol; 2008; 119(1):40-4. PubMed ID: 18253025
    [No Abstract]   [Full Text] [Related]  

  • 12. [[Antiresorptive agents in the treatment of osteoporosis].
    Novak S
    Reumatizam; 2014; 61(2):89-94. PubMed ID: 25427401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Title of news article on zoledronic acid and bone density was misleading.
    Goh S
    BMJ; 2015 May; 350():h2337. PubMed ID: 25952031
    [No Abstract]   [Full Text] [Related]  

  • 14. Report: Osteocyte enhancement function of bisphosphonates in prosthetic replacement.
    Yang J; Wang S; Meng Q; Sun Y; Ran AF
    Pak J Pharm Sci; 2015 May; 28(3 Suppl):1167-9. PubMed ID: 26051741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The use of bisphosphonates in arthroplasty].
    Eberhardt C; Habermann B; Kurth AA
    Orthopade; 2007 Feb; 36(2):141-5. PubMed ID: 17219189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of alendronate on bone mineral density in the distal part of the femur and proximal part of the tibia after total knee arthroplasty.
    Wang CJ; Wang JW; Weng LH; Hsu CC; Huang CC; Chen HS
    J Bone Joint Surg Am; 2003 Nov; 85(11):2121-6. PubMed ID: 14630840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of bisphosphonates in preventing femoral periprosthetic bone resorption after primary cementless total hip arthroplasty: a meta-analysis.
    Zhao X; Hu D; Qin J; Mohanan R; Chen L
    J Orthop Surg Res; 2015 May; 10():65. PubMed ID: 25962791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etidronate does not suppress periprosthetic bone loss following cemented hip arthroplasty.
    Fokter SK; Komadina R; Repse-Fokter A; Yerby SA; Kocijancic A; Marc J
    Int Orthop; 2005 Dec; 29(6):362-7. PubMed ID: 16193347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the effects of alendronate and alfacalcidol on bone mineral density around the femoral implant and in the lumbar spine after total hip arthroplasty.
    Iwamoto N; Inaba Y; Kobayashi N; Ishida T; Yukizawa Y; Saito T
    J Bone Joint Surg Am; 2011 Jul; 93(13):1203-9. PubMed ID: 21776573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of anti-osteoporosis drugs in total knee arthroplasty.
    Carulli C; Civinini R; Matassi F; Villano M; Innocenti M
    Aging Clin Exp Res; 2011 Apr; 23(2 Suppl):38-9. PubMed ID: 21970917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.